共 42 条
[1]
Motzer RJ(2007)Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115-124
[2]
Hutson TE(2007)Gastrointestinal perforation due to bevacizumab in colorectal cancer Ann Surg Oncol 14 1860-1869
[3]
Tomczak P(2007)Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 5180-5186
[4]
Saif MW(2007)Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab J Thorac Oncol 2 571-573
[5]
Elfiky A(2006)Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25-35
[6]
Salem RR(2006)Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329-1338
[7]
Cannistra SA(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342
[8]
Matulonis UA(2008)Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013-2019
[9]
Penson RT(2008)Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium J Clin Oncol 26 76-82
[10]
Gray J(2007)Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 25 5165-5177